8-K: Windtree Therapeutics Navigates Financial Distress with New Debt, Strategic Acquisitions, and Asset Sales

Windtree Therapeutics, Inc. has secured new convertible debt and is pursuing a dual strategy of acquiring an environmental services company and divesting preclinical oncology assets, while simultaneously addressing significant existing financial defaults.

Summary

• Windtree Therapeutics, Inc. (WINT) entered into a Note Purchase Agreement on June 5, 2025, with DFU, LLC, issuing a Convertible Promissory Note with a principal amount of $3,600,000 and a warrant to purchase $2,700,000 worth of common stock, receiving gross proceeds of $3,100,000.
• The proceeds from the DFU financing are intended to retire convertible notes and preferred stock of Titan Environmental Services, Inc., facilitated by Windtree's purchase of a Senior Note from Standard Waste Services, LLC for $4,632,500 (principal amount $6,617,857 due to original issuance discount).
• On June 9, 2025, Windtree secured an additional $800,000 through Note Purchase Agreements with Keystone Capital Partners, LLC, Seven Knots, LLC, C/M Capital Master Fund LP, and WVP Emerging Manager Onshore Fund, issuing convertible notes and warrants; these notes are subordinate to the DFU note.
• The company received a non-binding Letter of Intent on June 7, 2025, for the potential sale of its VAR 101 preclinical oncology assets, intellectual property, and pre-clinical data for $7 million upfront (cash or freely trading shares), with potential milestone payments up to $130 million and royalties up to $1.5 billion.
• Windtree also entered into a Letter of Intent on June 6, 2025, for the potential acquisition of Titan Environmental Services, Inc. for $35 million in Series E Preferred Stock, including bridge financing of an initial $750,000 convertible note and two subsequent $500,000 notes.
• The company disclosed a default on its office lease agreement for $159,800.65 (March, April, May 2025 rent and January-May 2025 utilities) and a default on the Aubrey Purchase and Sale Agreement, risking a $1.4 million payment.
• All convertible notes carry a 14% annual interest rate, compounding quarterly, which increases to 24% upon an Event of Default, compounding daily.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the immediate financial distress indicated by multiple defaults and the high-cost, dilutive nature of the new debt. While strategic pivots (acquisition, asset sale) are being pursued, they are currently non-binding or in early stages, and the underlying financial health appears precarious.

Positives

• The company is actively pursuing strategic diversification by entering the environmental services sector, a market valued at $85 billion in 2024 with historically attractive EBITDA margins and free cash flow.
• The potential sale of preclinical oncology assets could provide non-dilutive cash of $7 million upfront and significant future milestone payments up to $130 million, plus royalties up to $1.5 billion, allowing the company to monetize non-core assets.
• The Titan acquisition includes an $8 million breakup fee if the transaction is not consummated, providing a potential financial safeguard.

Negatives

• Windtree is facing immediate financial distress, evidenced by defaults on its office lease ($159,800.65) and a property purchase agreement ($1.4 million at risk).
• The newly issued convertible notes carry a high annual interest rate of 14%, escalating to 24% upon an Event of Default, indicating a high cost of capital due to perceived risk.
• The June 9 convertible notes are explicitly subordinate to the June 5 convertible note, meaning their holders will not receive principal or interest payments until the DFU note is fully repaid, increasing risk for these investors.
• The company's obligation to issue shares upon conversion of notes and warrants is absolute, regardless of dilutive effect on existing shareholders.

Risks

• Failure to cure existing defaults on the office lease and Aubrey Property purchase agreement could lead to lease termination, dispossession, and loss of the $1.4 million payment.
• The non-binding nature of the asset sale and acquisition Letters of Intent means these transactions may not close, impacting the company's strategic and financial plans.
• High interest rates on convertible notes (14%, escalating to 24% on default) could significantly increase debt servicing costs, especially if defaults occur.
• Potential for substantial shareholder dilution upon conversion of the convertible notes and exercise of warrants, as the conversion price is fixed at $0.587.
• The company's ability to maintain NASDAQ listing is a risk, as delisting is an Event of Default for the convertible notes.
• Failure to timely comply with SEC reporting requirements or maintain publicly available information could trigger an Event of Default.
• The company's ability to secure additional capital as needed and manage costs effectively remains a significant risk factor.

Future Outlook

Windtree Therapeutics aims to become a revenue-generating company by diversifying into growing industries, specifically targeting the waste management sector through the acquisition of Titan Environmental Services. The company also intends to reduce costs and increase overall profitability by evaluating options for its drug candidate pipeline, including the potential sale of its preclinical oncology assets. Management expects the Titan acquisition to close in Q3 and generate $12 million in revenue over the next 12 months, leading to a profitable business with growth opportunities via a roll-up strategy.

Management Comments

• Jed Latkin, CEO of Windtree, stated: 'This transaction strategically aligns with our vision of diversifying our business model by increasing revenue and providing significant growth potential for the Company.'
• Jed Latkin also commented: 'We look forward to working with the Titan management and continuing to execute on our refined corporate strategy.'
• Regarding the oncology asset sale, Jed Latkin said: 'This offer may provide the company non-dilutive cash and potential for a very lucrative milestone and royalty stream.'
• Jed Latkin further noted: 'We do not view the preclinical oncology aPKCi assets as a core part of our vision going forward but want to make sure that our current shareholders benefit from the development of the assets.'
• Jed Latkin emphasized: 'Furthermore, we are very intently looking at all options to increase shareholder value by reducing the current cashflow burn and focusing on near term accretive opportunities.'

Industry Context

Windtree Therapeutics is pivoting from a primary focus on pharmaceuticals to a diversified business model, with a significant move into the U.S. environmental services market. This market was valued at $85 billion in 2024 and is characterized by its fragmented nature, offering opportunities for a 'roll-up strategy' through acquisitions to drive revenue growth and positive EBITDA contributions. This strategic shift aims to leverage the attractive EBITDA margins and free cash flow historically generated in the waste management industry, contrasting with the high-risk, long-development cycles typical of the pharmaceutical sector.

Comparison to Industry Standards

• The U.S. waste collection market, which Windtree is entering via the Titan acquisition, was valued at $85 billion in 2024 and has historically generated attractive EBITDA margins and free cash flow, suggesting a potentially more stable and profitable business model compared to the high-risk pharmaceutical industry.
• The high interest rates (14% to 24% on default) on the newly issued convertible notes are significantly above typical corporate borrowing rates for financially stable companies, indicating a high-risk profile and potentially limited access to conventional financing for Windtree.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a notice of default on June 2, 2025, regarding its office lease agreement for nonpayment of rent and utilities totaling $159,800.65. The landlord reserves the right to terminate the lease and dispossess the company.
• The company received a notice of default on May 30, 2025, with respect to the Aubrey Purchase and Sale Agreement for failing to close the transaction by the deadline, risking the loss of $1.4 million paid towards the property.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the conversion of new notes and exercise of warrants. The strategic shift into environmental services and potential asset sale could create long-term value, but the immediate financial distress and high-cost debt pose substantial risks to current equity value.
• **Employees**: Titan's current management team is expected to be retained, suggesting continuity for employees of the acquired entity. Windtree's overall strategy to reduce cash burn may imply cost-cutting measures that could affect its existing workforce.
• **Customers**: The acquisition of Titan Environmental Services aims to expand Windtree's operational scope, potentially offering new or expanded services to customers in the waste management sector.
• **Suppliers**: The company's financial defaults could impact its ability to pay suppliers, as evidenced by the lease default. Successful strategic pivots could improve supplier relationships.
• **Creditors**: The DFU convertible note holds senior unsecured priority over all existing and future indebtedness, while the June 9 notes are subordinate to the DFU note. This creates a clear hierarchy among creditors, with some holding a more favorable position than others. Existing creditors related to the defaulted lease and property purchase face immediate risk.

Next Steps

• Negotiate with the landlord to cure outstanding defaults on the office lease.
• Negotiate with the Aubrey Seller to cure outstanding defaults under the Aubrey Agreement.
• Work towards closing the non-binding asset sale of VAR 101 and other Varian assets within 21 days.
• Negotiate definitive documentation for the Titan Environmental Services, Inc. acquisition within a 60-day exclusivity period, with an aim to close in Q3.
• Titan Environmental Services, Inc. is required to provide PCAOB audited financial statements for 2023 and 2024 by June 15, 2025, and reviewed financials for Q1 and Q2 2025 by August 15, 2025.
• File a registration statement on Form S-1 with the SEC within 20 trading days from June 5/9, 2025, to register the offering and resale of shares underlying the convertible notes and warrants.
• Implement and execute a 'roll-up strategy' in the waste management industry following the Titan acquisition.

Key Dates

Recommendation

Keywords

Windtree Therapeutics, WINT, SEC Filing, 8-K, Convertible Note, Promissory Note, Warrant, Capital Raise, Acquisition, Asset Sale, Environmental Services, Oncology, Pharmaceutical, Debt Financing, Financial Default, NASDAQ, Corporate Strategy, Diversification, Dilution